IGFBP-3 in Ovarian Cancer Invasion

Sponsor

National Taiwan University Hospital (Other)

Overall Status

Unknown status

CT.gov ID

NCT00154986

Collaborator

(none)

Enrollment

Location

Duration (Months)

2.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Carcinoma	Procedure: immunohistochemical staining, transfection, invasion assay	N/A

Detailed Description

We have successfully established an ovarian cancer cell line (OVTW-59), which was derived from an ovarian endometrioid carcinoma. Its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities, were selected from transwell invasion chambers, where P0 represented the original cell line at 100th passage. By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma. From these genes, we selected insulin-like growth factor binding protein (IGFBP)-3, which is a suppressor gene, and found it lower expressed in higher-grade tumors and correlated with poor patient survival. In vitro, we found IGFBP-3 related to the inhibition of cancer cell migration. In this study, we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4, and study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy.

Study Design

Study Type:

Interventional

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

Single

Primary Purpose:

Diagnostic

Official Title:

Study of IGFBP-3 in the Ovarian Carcinoma Cell Invasion

Study Start Date :

Aug 1, 2004

Study Completion Date :

Jul 1, 2005

Outcome Measures

Primary Outcome Measures

migration, invasion, metastasis []

Secondary Outcome Measures

transfection efficiency []

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years to 80 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Ovarian Endometrioid Adenocarcinoma

Exclusion Criteria:

Other types of ovaria epithelial cell carcinoma

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Taiwna University Hospital	Taipei		Taiwan	10020

Sponsors and Collaborators

National Taiwan University Hospital

Investigators

Principal Investigator: Torng Pao-Ling, MD, PhD, Department of Obsteteric and Gynecology, National Tiawan University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT00154986

Other Study ID Numbers:

9361700500
NSC93-2314-B-002-168

First Posted:

Sep 12, 2005

Last Update Posted:

Sep 12, 2005

Last Verified:

Apr 1, 2004

Keywords provided by , ,

Additional relevant MeSH terms:

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Study Results

No Results Posted as of Sep 12, 2005